Jiangsu Jinsan Biotechnology Co., Ltd. recently announced the completion of its Pre-A round financing exceeding RMB 100 million (approx. USD 13.8 million), led by GGV Capital Asia. The funding will be used to upgrade ergothioneine production lines, expand its terminal product portfolio, and build international certification systems. As a leading global supplier of the antioxidant ergothioneine, Jinsan Bio leverages synthetic biology to overcome the efficiency and cost limitations of natural extraction. The company is targeting the trillion-yuan anti-aging market and is actively exploring applications in functional skincare, precision nutrition, eye health, sleep, and metabolic disorders. (Source: Sina Finance)
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE